Kidney and Blood Pressure Research
Original Paper
Fetuin-A Early after Renal TransplantationUrbanová M.a · Kalousová M.b · Zima T.b · Skibová J.a · Wohlfahrt P.d · Viklický O.a, caDepartment of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, bInstitute of Clinical Chemistry and Laboratory Diagnostics, General University Hospital and Charles University Faculty of Medicine I, cTransplant Laboratory, Institute for Clinical and Experimental Medicine, and dDepartment of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: July 20, 2009
Issue release date: August 2009
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2
ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)
For additional information: https://www.karger.com/KBR
Abstract
Background: Fetuin-A is a major inhibitor of ectopic calcium phosphate precipitation and an acute phase reactant. Its deficiency, common in end-stage renal disease, has been suggested to be associated with cardiovascular complications. The aim of this study was to monitor fetuin-A levels in the early period after renal transplantation. Methods: 30 deceased donor kidney recipients treated with calcineurin inhibitor-based immunosuppression were followed prospectively for the first 3 months and the association of fetuin-A levels with clinical and laboratory parameters was evaluated. Results: Despite a correlation of fetuin-A levels with creatinine clearance (r = 0.348, p < 0.01) and estimated GFR (r = 0.331, p < 0.01), no significant increase in fetuin-A levels over the first 3 months was observed. Moreover, a significant decrease in serum fetuin-A levels was noted at 2 weeks (p < 0.001). Subsequently, fetuin-A levels increased (p < 0.001) reaching pretransplant values at month 3. Conclusions: In this study there was no increase of fetuin-A levels during the first 3 months, but a decrease 2 weeks after transplantation was observed.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Keteller M, Bongartz P, Westenfeld R, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827–833.
- Lebreton JP, Joisel F, Raoult JP, et al: Serum concentration of human α2-HS glycoprotein during inflammatory process. Evidence that α2-HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118–1129.
- Schafer C, Heiss A, Schwarz A, et al: The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357–366.
- Price PA, Nguyen TM, Williamson MK: Biochemical characterization of the serum fetuin mineral complex. J Biol Chem 2003;278:22153–22160.
- Reynolds JL, Skepper JN, McNair R, et al: Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920–2930.
- Jahnen-Dechent W, Schinke T, Trindl A, et al: Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 1997;272:31496–31503.
- Szweras M, Liu D, Partridge EA, et al: α2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991–19997.
- Mathews ST, Singh GP, Ranalletta M, et al: Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002;51:2450–2458.
- Demetriou M, Binkert C, Sukhu B, et al: Fetuin/α2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755–12761.
- Van Summeren MJ, Hameleers JM, Schurgers LJ, et al: Circulating calcification inhibitors and vascular properties in children after renal transplantation. Pediatr Nephrol 2008;23:985–993.
- Caglar K, Yilmaz MI, Saglam M, et al: Endothelial dysfunction and fetuin-A levels before and after kidney transplantation. Transplantation 2007;83:392–397.
- Ciaccio M, Bivona G, Di Sciacca R, et al: Changes in serum fetuin-A and inflammatory marker levels in end-stage renal disease: effect of a single session haemodialysis. Clin Chem Lab Med 2008;46:212–214.
- Wang AY, Woo J, Lam CW, et al: Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676–1685.
- Van Oss CJ, Bronson PM, Border JR: Changes in the serum α-glycoprotein distribution in trauma patients. J Trauma 1975;15:451–455.
-
Kundranda MN, Henderson M, Carter KJ: The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms. Cancer Res 2005;6:499–506.
- Carrero JJ, Stenvinkel P, Fellström B, et al: Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med 2008;263:302–312.
Article / Publication Details
Published online: July 20, 2009
Issue release date: August 2009
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2
ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)
For additional information: https://www.karger.com/KBR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
